enoxaparin sodium injection is commonly used, and its indication is to prevent deep vein thrombosis and pulmonary embolism. Treatment of existing venous thrombosis; Prevent the formation of thrombus during cardiopulmonary bypass during hemodialysis; Treatment of unstable angina pectoris and non-Q wave myocardial infarction.

　　Enoxaparin sodium is a kind of low molecular weight heparin, the average weight molecular weight is about 4500 Dalton, AXa/AIIa is about 3.3~5.3, is currently the best sale of low molecular weight heparin. Compared with standard heparin, low molecular weight heparin has the following advantages: there is no need to monitor thrombin time parameters; Less potential bleeding risk; Low risk of osteoporosis with long-term use; Low risk of thrombocytopenia.

　　At present, there are ordinary low molecular weight heparin injections in the domestic market, whose average weight molecular weight is less than 8000 Da, and AXa/AIIa is not less than 1.5. Compared with ordinary low molecular weight heparin, enoxparin sodium has the following obvious advantages: lower weight average molecular weight, larger AXa/AIIa value, and longer half-life, which make enoxparin sodium safer and more effective than ordinary low molecular weight heparin.